SEC Tracker
Get the app
ACRS · XBRL financial data

Aclaris Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ACRS's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers918*2349*1231*22
Cost of revenue11*1111*1111*00
Research and development2427*10969*12111317*1618
General and administrative78*7565*6556*76
Operating income (loss)(32)(4)*(19)(13)(10)(100)*(18)(18)(17)(23)*(22)(24)
Interest income22*2222*2222*22
Other income (expense)22*22————————
Income tax expense (benefit)—year only——————————
Net income (loss)(29)(1)*(17)(11)(8)(97)*(15)(15)(15)(20)*(20)(22)
Earnings per share, basic USD per share(0.41)(0.02)*(0.24)(0.15)(0.11)—(0.12)(0.13)(0.12)(0.16)*(0.15)(0.15)
Earnings per share, diluted USD per share(0.41)(0.02)*(0.24)(0.15)(0.11)—(0.12)(0.13)(0.12)(0.16)*(0.15)(0.15)
Weighted average shares, basic millions of shares7171*71717195*122123123123*129143
Weighted average shares, diluted millions of shares7171*71717195*122123123123*129143

Balance sheet

CSV

Fiscal quarters (ACRS's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents394036234825302525202919
Marketable securities647992888089757471717772
Marketable securities, non-current846333394690858171618579
Accounts receivable00000000————
Prepaid and other current assets2097641234————
Total current assets1231291351181321261091041019611098
Property and equipment, net222111111111
Total assets218197174161182220198189176160199180
Accounts payable10911785699131516
Accrued liabilities15197652091110966
Total current liabilities273120161932222726292728
Lease liability, non-current233222222211
Total liabilities624032275265545755575555
Accumulated deficit(769)(771)(788)(799)(806)(903)(918)(933)(948)(968)(988)(1,009)
Total stockholders' equity156157142134130156144132120103144125
Total liabilities and equity218197174161182220198189176160199180
Common shares outstanding (cover page) millions of shares7171717171108108108108121140147

Cash flows

CSV

Fiscal quarters (ACRS's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(29)(1)*(17)(11)(8)(97)*(15)(15)(15)(20)*(20)(22)
Stock-based compensation6*1*23*3*3*43*3*3*33*
Depreciation and amortization0*0*00*0*0*00*0*0*00*
Net cash from operating activities(25)*(7)*(21)(12)*22*(9)*(13)(10)*(11)*(13)*(18)(20)*
Purchases of property and equipment0*0*0(0)*0*0*00*0*0*00*
Net cash from investing activities33*8*17(1)*3*(89)*195*14*10*(31)10*
Net cash from financing activities(0)*0*(0)(0)*0*75*(0)(0)*(3)*(3)*580*
Net change in cash8*1*(4)(13)*25*(23)*6(5)*(0)*(5)*9(9)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Aclaris Therapeutics191.6(20)*147.2M4.6 quarters 10-QJun 30, 2026
Alpha Cognition416.1(6.9)*21.8M6.0 quarters 10-QJun 30, 2026
Neurogene112not reported(24)*20.0M9.5 quarters 10-QJun 30, 2026
Sangamo Therapeutics281.4(19)414.3M1.4 quarters 10-QMar 31, 2026
Puma Biotechnology37571.6*51.6M— 10-QJun 30, 2026
Eledon Pharmaceuticals6.8not reported(23)*81.3M3.9 quarters 10-QJun 30, 2026
Voyager Therapeutics363.2(26)*61.6M4.5 quarters 10-QJun 30, 2026
Monopar Therapeutics530*(3.2)*6.7M32.4 quarters 10-QJun 30, 2026
Forte Biosciences50not reported(23)*21.2M8.7 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.